Expert oncologists Prof. Dominik Modest and Dr Sara Lonardi discuss their takeaways from two key clinical trials presented at ASCO 2025, and the potential implications for clinical practice.
The physicians discuss data from the following studies:
- BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant mCRC (BREAKWATER): progression-free survival and updated overall survival analyses. Elez E, et al. Abstract LBA3500, ASCO 2025
- CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC: expanded analyses from CheckMate 8HW. Lenz H-J, et al. Abstract 3501, ASCO 2025
Clinical takeaways
- BREAKWATER: demonstrated a statistically significant and clinically meaningful improvement in PFS and OS with encorafenib, cetuximab (EC) + mFOLFOX6 and establishes front-line EC and FOLFOX as the new standard of care for BRAF V600E–mutant mCRC.
- CheckMate-8HW: NIVO + IPI continued to demonstrate improved PFS vs NIVO in patients with MSI-H/dMMR mCRC across all lines of therapy providing further support for NIVO + IPI as the standard of care for patients with MSI-H/dMMR mCRC